Boston Scientific Enters Renal Denervation Market Via Vessix Acquisition
This article was originally published in The Gray Sheet
Executive Summary
Deal gives Boston Scientific access to the V2 radiofrequency energy-based renal denervation catheter system for drug-resistant hypertension.
You may also be interested in...
Medtronic Renal Denervation System Provides Durable Blood Pressure Benefits In Longest Trial To Date
The latest results from Medtronic’s SYMPLICITY HTN-2 trial show that patients treated for severe hypertension with the company’s Symplicity radio frequency renal denervation system showed a sustained reduction in blood pressure. The firm also announced the start of a renal denervation trial in patients with moderate hypertension.
EuroPCR in Brief
New clinical data from St. Jude Medical’s and Boston Scientific’s trials of renal denervation devices to treat hypertension show progress in the development of these novel blood pressure therapies, but both companies remain behind Medtronic. More news from EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions.
Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS
The device is one the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.